2. Academic Validation
  3. Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. Part 4: Heterocycles at C3

Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. Part 4: Heterocycles at C3

  • Bioorg Med Chem Lett. 2004 Jan 19;14(2):343-6. doi: 10.1016/j.bmcl.2003.11.008.
Eddy W Yue 1,  Susan V DiMeo,  C Anne Higley,  Jay A Markwalder,  Catherine R Burton,  Pamela A Benfield,  Robert H Grafstrom,  Sarah Cox,  Jodi K Muckelbauer,  Angela M Smallwood,  Haiying Chen,  Chong Hwan Chang,  George L Trainor,  Steven P Seitz
Affiliations

Affiliation

  • 1 Bristol-Myers Squibb Company, Experimental Station, PO Box 80500, Wilmington, DE 19880-0500, USA. eddyyue@incyte.com
PMID: 14698155 DOI: 10.1016/j.bmcl.2003.11.008
Abstract

New indeno[1,2-c]pyrazol-4-one cyclin dependent kinase inhibitors have been disclosed. The most promising compounds are nanomolar Enzyme inhibitors with excellent activity against tumor cells. The most advanced compound retains Cell Culture activity even in the presence of human serum proteins. The most advanced compound did not kill the normal fibroblast line AG1523.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-155602
    CDK2/E抑制剂
    CDK
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z